Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Teva
Merck
QuintilesIMS
Mallinckrodt
Federal Trade Commission
Cantor Fitzgerald
Citi
Medtronic
Queensland Health

Generated: February 22, 2018

DrugPatentWatch Database Preview

Biogen Idec Company Profile

« Back to Dashboard

Summary for Biogen Idec
International Patents:595
US Patents:14
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Biogen Idec

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 RX Yes Yes 8,399,514 ➤ Try a Free Trial ➤ Try a Free Trial
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes 8,980,853 ➤ Try a Free Trial ➤ Try a Free Trial
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 RX Yes Yes 8,759,393 ➤ Try a Free Trial Y ➤ Try a Free Trial
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 RX Yes No 7,320,999 ➤ Try a Free Trial ➤ Try a Free Trial
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 RX Yes No 7,619,001 ➤ Try a Free Trial ➤ Try a Free Trial
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 RX Yes No 8,399,514 ➤ Try a Free Trial ➤ Try a Free Trial
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 RX Yes Yes 7,619,001 ➤ Try a Free Trial ➤ Try a Free Trial
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 RX Yes Yes 8,524,773 ➤ Try a Free Trial ➤ Try a Free Trial
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 RX Yes No 8,759,393 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BIOGEN IDEC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-releaseCapsules 120 mg and 240 mg ➤ Subscribe 3/27/2017

Non-Orange Book US Patents for Biogen Idec

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,172,216 Antisense modulation of BCL-X expression ➤ Try a Free Trial
7,612,110 Utilization of dialkylfumarates ➤ Try a Free Trial
9,476,042 Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences ➤ Try a Free Trial
7,915,310 Utilization of dialkylfumarates ➤ Try a Free Trial
8,946,183 Compositions and methods for modulation of SMN2 splicing ➤ Try a Free Trial
6,214,986 Antisense modulation of bcl-x expression ➤ Try a Free Trial
8,586,559 Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences ➤ Try a Free Trial
9,107,933 Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III ➤ Try a Free Trial
7,148,204 Antisense modulation of bcl-x expression ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Biogen Idec Drugs

Supplementary Protection Certificates for Biogen Idec Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00036 Denmark ➤ Try a Free Trial PRODUCT NAME: DIMETHYL FUMARAT (DIMETHYLFUMARAT); REG. NO/DATE: EU/1/13/837/001-002 20140130
C/GB03/005 United Kingdom ➤ Try a Free Trial PRODUCT NAME: D-MEDETOMIDINE (4-((1S)-1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE) AND ITS NON-TOXIC PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE HYDROCHLORIDE; REGISTERED: UK EU/2/02/033/001 20020830
2014 00055 Denmark ➤ Try a Free Trial PRODUCT NAME: TRAMETINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HYDRAT ELLER SOLVAT DERAF, HERUNDER TRAMETINIBDIMETHYLSULFOXID; REG. NO/DATE: EU/1/14/931/01-06 20140630
0902 Netherlands ➤ Try a Free Trial PRODUCT NAME: NUSINERSEN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/17/1188 20170601
487 Luxembourg ➤ Try a Free Trial PRODUCT NAME: DIMETHYL FUMARATE. FIRST REGISTRATION: 20140203
90039-3 Sweden ➤ Try a Free Trial PRODUCT NAME: DIMETHYL FUMARATE; REG. NO/DATE: EU/1/13/837 20140130
2017 00055 Denmark ➤ Try a Free Trial PRODUCT NAME: NUSINERSEN ELLER SALTE DERAF; REG. NO/DATE: EU/1/17/1188 20170601
0905 Netherlands ➤ Try a Free Trial PRODUCT NAME: NUSINERSEN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/17/1188 20170601
8 Finland ➤ Try a Free Trial
2014 00035 Denmark ➤ Try a Free Trial PRODUCT NAME: DIMETHYL FUMARAT (DIMETHYLFUMARAT); REG. NO/DATE: EU/1/13/837/001-002 20140130
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Fuji
Johnson and Johnson
McKesson
Teva
Daiichi Sankyo
Citi
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot